Structural basis for allosteric PARP-1 retention on DNA breaks

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

(2018) Sibylle Loibl et al.   LANCET ONCOLOGY

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

(2018) Alan Ashworth et al.   Nature Reviews Clinical Oncology

NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains

(2018) Marie-France Langelier et al.   Nature Communications

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets

(2018) Dragomir B. Krastev et al.   Nature Communications

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

(2018) Stephen J. Pettitt et al.   Nature Communications

PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer

(2018) Roman M. Chabanon et al.   JOURNAL OF CLINICAL INVESTIGATION

PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes

(2017) Rebecca Gupte et al.   GENES & DEVELOPMENT

Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers

(2017) Amy Dréan et al.   MOLECULAR CANCER THERAPEUTICS

PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1

(2017) Lili Liu et al.   NUCLEIC ACIDS RESEARCH

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells

(2017) Pepijn M. Schoonen et al.   Nature Communications

Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation

(2016) B. A. Gibson et al.   SCIENCE

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

(2016) Y. Pommier et al.   Science Translational Medicine

The rise and fall of poly(ADP-ribose): An enzymatic perspective

(2015) John M. Pascal et al.   DNA REPAIR

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

(2015) Robert L. Coleman et al.   GYNECOLOGIC ONCOLOGY

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

(2015) T. A. Hopkins et al.   MOLECULAR CANCER RESEARCH

Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1

(2015) Sebastian Eustermann et al.   MOLECULAR CELL

PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain

(2015) Jennine M. Dawicki-McKenna et al.   MOLECULAR CELL

PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1

(2014) Marie-France Langelier et al.   NUCLEIC ACIDS RESEARCH

Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2

(2014) Wei Qiu et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer

(2014) Taofeek K. Owonikoko et al.   Cancer Medicine

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis

(2013) Marie-France Langelier et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Histone ADP-Ribosylation Facilitates Gene Transcription by Directly Remodeling Nucleosomes

(2012) R. Martinez-Zamudio et al.   MOLECULAR AND CELLULAR BIOLOGY

Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1

(2012) M.-F. Langelier et al.   SCIENCE

REFMAC5 for the refinement of macromolecular crystal structures

(2011) Garib N. Murshudov et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Overview of theCCP4 suite and current developments

(2011) Martyn D. Winn et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Synthetic lethality: exploiting the addiction of cancer to DNA repair

(2011) M. Shaheen et al.   BLOOD

Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations

(2011) Konstantin J. Dedes et al.   CELL CYCLE

Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA

(2011) Marie-France Langelier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

XDS

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

PHENIX: a comprehensive Python-based system for macromolecular structure solution

(2010) Paul D. Adams et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements

(2010) Shinji Mizuarai et al.   HUMAN GENETICS

The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction

(2010) Marie-France Langelier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity

(2008) Christopher J. Lord et al.   DNA REPAIR

Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer

(2008) Thomas D. Penning et al.   JOURNAL OF MEDICINAL CHEMISTRY